ロード中...
Epoetin β pegol (continuous erythropoietin receptor activator, CERA) is another choice for the treatment of anemia in myelodysplastic syndrome: a case report
BACKGROUND: In most patients, anemia is present when myelodysplastic syndrome is diagnosed. Although darbepoetin α is the first-choice supportive therapy for low-risk myelodysplastic syndrome, half of all patients develop a loss of response to darbepoetin α within 12 months. However, few reports hav...
保存先:
| 出版年: | J Med Case Rep |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5648440/ https://ncbi.nlm.nih.gov/pubmed/29047386 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13256-017-1468-z |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|